Similar Efficacy and Safety of Basaglar(®) and Lantus(®) in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

INTRODUCTION: To compare efficacy and safety of Basaglar(®) [insulin glargine 100 units/mL; LY insulin glargine (LY IGlar)] to Lantus(®) [insulin glargine 100 units/mL; SA insulin glargine (SA IGlar)] in older (≥ 65 years) or younger (< 65 years) patients with type 2 diabetes (T2D). METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollom, Robyn K., Costigan, Timothy, Lacaya, Lyndon B., Ilag, Liza L., Hollander, Priscilla A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104266/
https://www.ncbi.nlm.nih.gov/pubmed/29542012
http://dx.doi.org/10.1007/s13300-018-0405-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104266/
https://www.ncbi.nlm.nih.gov/pubmed/29542012
http://dx.doi.org/10.1007/s13300-018-0405-5

Ejemplares similares